Biotech | September 03, 2021
Omeza Collegen Matrix gets U.S. FDA approval
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
Coordinated and collaborative efforts will strongly contribute to the achievement of shared goals faster: Mandaviya
PPH is associated with almost 20 per cent of maternal mortality in India
Subscribe To Our Newsletter & Stay Updated
